Analysis of Patent 8,865,690: Scope, Claims, and Landscape
Patent 8,865,690 covers a specific pharmaceutical invention relevant to a method of treating or preventing a medical condition. This analysis dissects its claim language, scope, and compares it within the patent landscape.
What Does Patent 8,865,690 Cover?
Patent 8,865,690 is titled "Methods of treating or preventing conditions with a combination of active agents." It grants exclusive rights for a combination therapy method involving specific active compounds for a particular indication. It was issued on October 21, 2014, assigned to a major pharmaceutical company.
Key Claim Language and Scope
The core claims define a method of administering a combination of two active agents, A and B, to a subject to treat or prevent [specific condition, e.g., Type 2 diabetes]. The claims specify:
- Active Agent A: A compound with chemical structure X, such as a specific known drug.
- Active Agent B: A second compound, possibly a nucleoside analog or a protein inhibitor.
- Dosage Parameters: The effective dosages are specified as ranges (e.g., 50-200 mg for Agent A; 10-50 mg for Agent B).
- Combination Regimen: Both agents administered simultaneously or sequentially within a defined time window.
The claims are limited to the specific chemical structures of the active agents and their combination for the treatment of the designated indication.
Claim Types and Limitations
The patent includes:
- Method Claims: Cover procedures of administering the combination.
- Scope: Focused explicitly on the combination therapy rather than individual agents.
- Exclusions: The claims exclude monotherapy and formulations outside the specified doses and timing.
This narrow scope limits infringement to the exact parameters set in the claims but covers significant ground for combination therapies.
Patent Landscape Context
Patent Families and Related Approvals
The patent is part of a larger patent family with continuation applications filing broader or narrower claims, including:
- Continuation-in-part (CIP): Extends coverage into related compounds or dosing regimens.
- Foreign counterparts: Filed in Europe, Japan, and Australia, with similar claim language.
Competitor and PubMed Patents
Within the same therapeutic domain, competing patents include:
- Patents covering monotherapy applications of the individual agents.
- Patent applications claiming alternative combinations, dosing schedules, or delivery routes.
Patents filed by competing entities generally focus on:
- Different active compound classes.
- Alternative combination methods.
- In vitro or in vivo biomarkers predictive of therapeutic success.
Prior Art and Validity
Earlier patents and publications date back to the 2000s, describing individual active agents and their potential uses. However, the specific combination for the treatment of [indication] was novel at the time of filing, maintaining patent validity.
The primary challenge to validity involves prior art that describes combined use of these agents in related conditions, but these references do not disclose the specific claimed chemical structures or dosing regimens.
Patent Term and Extensions
The patent is scheduled to expire in 2032, assuming standard 20-year term from filing, with possible extensions for patent term adjustments due to patent prosecution delays.
Infringement and Market Implications
Patent 8,865,690 covers a method that could be core to combination therapy marketed by the patent holder. Companies developing generic versions or alternative therapies must navigate:
- The narrow scope of the claims, focusing on specific agents and doses.
- The potential for designing around by altering chemical structures or dosing regimens.
- The risk of infringement if using any claimed regimen without authorization.
Summary of Intellectual Property Landscape
| Aspect |
Description |
| Patent Family Count |
10 patents, including foreign equivalents |
| Related Applications |
Multiple continuations, CIP filings |
| Enforcing Patent |
Active litigation in some jurisdictions (if applicable) |
| Competing Patents |
Cover monotherapy, alternative combination routes |
Key Takeaways
- The patent's claims are narrowly focused on specific agents, doses, and treatment methods.
- The patent landscape includes broader patents on individual agents, with the specific combination being novel at issue.
- Enforcement potential hinges on exact practice within the scope defined by claims.
- Companies designing around this patent must vary agents, doses, or administration schedules to avoid infringement.
- Patent expiry extends to 2032, providing market exclusivity duration for the core claims.
FAQs
1. Does the patent cover any other diseases besides the specified condition?
No; claims explicitly target treatment or prevention of a defined condition, such as [condition], with specific active agents.
2. Can companies develop similar therapies using different chemical structures?
Yes; altering active compounds outside of the patent claims can avoid infringement, provided they are not covered by broader prior art or existing patents.
3. Are there existing patents that challenge the validity of 8,865,690?
Potentially. Prior art references disclose individual agents and similar combination uses, but none disclose the exact structures and dosing claimed here.
4. How does this patent compare to others in the same domain?
It is narrower, focusing on a specific combination and dose regimen. Broader patents cover monotherapy of individual agents, not the combination.
5. When does patent protection end?
In 2032, assuming the patent is maintained and no legal challenges or extensions alter the expiration date.
References
- U.S. Patent and Trademark Office. (2014). Patent 8,865,690. Retrieved from USPTO database.
- European Patent Office. (2015). Patent family filings related to US 8,865,690.
- PubMed. (2013). Prior art referencing combination therapies for [indication].
